FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer.
The regimen consists of: This cycle is typically repeated every two weeks.
FOLFIRI is often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate.
[3] In the short term, irinotecan causes diarrhea, which may be acute or delayed in onset.
Long term use[citation needed] of irinotecan may lead to neutropenia.